SCHEMBL344376

SCHEMBL344376

O=C(O)c1c(F)c(Br)c2ccccn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 3/20 0.40
FNTB P49356 3/20 0.40
HTT P42858 1/20 0.38
KMT2A Q03164 4/20 0.37
IDO1 P14902 1/20 0.37
MEN1 O00255 2/20 0.36
PTGS2 P35354 2/20 0.36
CHEK1 O14757 1/20 0.34
FYN P06241 1/20 0.34
PDGFRB P09619 1/20 0.34
PIM1 P11309 1/20 0.34
FGFR1 P11362 1/20 0.34
GRK5 P34947 1/20 0.34
KDR P35968 1/20 0.34
MAP2K2 P36507 1/20 0.34
MAPK8 P45983 1/20 0.34
CDK8 P49336 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
NEK2 P51955 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL344481 0.78 KDM4E (0.53) HTTKMT2AIDO1MEN1L3MBTL1
SCHEMBL29059904 0.76 KMT2A (0.42) FNTAFNTBHTTKMT2AIDO1
SCHEMBL7521282 0.70 IDO1 (0.43) FNTAFNTBKMT2AIDO1MEN1
SCHEMBL30549316 0.69 KMT2A (0.54) FNTAFNTBHTTKMT2AMEN1
SCHEMBL9098561 0.69 PTGS2 (0.51) FNTAFNTBHTTKMT2AIDO1
SCHEMBL22776023 0.69 FNTA (0.34) FNTAFNTBHTTKMT2ARORC
SCHEMBL4221626 0.67 HTT (0.48) FNTAFNTBHTTKMT2AMEN1
SCHEMBL345108 0.66 ALDH1A1 (0.43) KMT2AIDO1MEN1FGFR1L3MBTL1
SCHEMBL4225404 0.66 HTT (0.47) FNTAFNTBHTTKMT2AMEN1
SCHEMBL27398782 0.66 FNTA (0.48) FNTAFNTBKMT2AIDO1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102365281-B Indolizine derivative and medical application thereof KISSEI PHARMACEUTICAL 2014-11-12 CN disclosed
US-8748452-B2 Indolizine derivative and use thereof for medical purposes KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-06-10 US disclosed
EP-2415771-B1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL (JP) 2013-07-31 EP disclosed
EP-2415771-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES Kissei Pharmaceutical Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES XDH, INMT, PON1 FNTA 2059/4885FNTB 3668/4885HTT 2283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.